← The Cooper Companies overview

The Cooper Companies vs Neogen: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

The Cooper Companies, Inc (COO)

Q3 2026
▼2▲1

CooperSurgical retained, guidance cut, activist fight escalates

  • Strategic review ends without sale Cooper ended its nine-month review by keeping CooperSurgical after bids came in too low, dashing hopes for a value-unlocking sale and sending shares to a 52-week low near $51.

    The failed sale removed a major potential catalyst and directly pressured the stock.

  • Fiscal 2026 guidance cut The company slashed its fiscal 2026 guidance, a sign that business conditions are weakening and future profits will be lower than expected, which drove a sharp drop in the share price.

    Guidance cuts directly lower earnings expectations and are a primary reason the stock fell.

  • Activist pressure intensifies Jana Partners, an activist investor, initially lifted shares on hopes for a shake-up, but is now pushing to replace the CEO and board chair and may launch a proxy fight, adding uncertainty.

    Activist involvement is a major force behind the stock's volatility and future direction.

  • Buyback and product innovation The board authorized a new $1 billion buyback, expanding the program to $3 billion, and CooperVision opened a UK innovation hub and unveiled six lens advances, supporting future growth.

    These are the main positive offsets to the negative news, showing capital return and product momentum.

August 2026
▲2▼2

Cooper keeps surgical unit, cuts outlook; activist Jana escalates for CEO change

  • CooperSurgical sale review ends with no deal, guidance cut Cooper ended its nine-month review and kept CooperSurgical because bids were too low, then reported a weak quarter and cut its outlook. Shares fell about 15% to a 52-week low near $51, as investors lost hope a sale would unlock value.

    This is the period's biggest negative force on COO's price and the core reason it is moving.

  • New $1 billion buyback authorized alongside the no-sale decision The board approved a fresh $1 billion share repurchase to show confidence in keeping CooperSurgical. Buying back stock shrinks the number of shares and can support the price, but it did not offset the drop from the weak outlook.

    It is the main offsetting positive action announced with the negative review outcome.

  • New innovation hub and six lens product advances CooperVision opened a global innovation hub in England and unveiled six contact-lens advances, including myopia-control and silicone hydrogel products launching over several years. The stock rose 1.4% on the news, a modest lift to the long-term growth story.

    It is a genuinely new positive development supporting future revenue growth.

  • Jana escalates, pushing to replace CEO and sell businesses Jana Partners is pressing Cooper to replace CEO Albert White and the board chair and to explore selling CooperVision or CooperSurgical, threatening a proxy fight. The stock is down about 28% since Jana first disclosed its stake, keeping pressure on management.

    It is the latest activist escalation and a key force behind the stock's uncertainty.

Latest
▲2▼2

Cooper keeps surgical unit, cuts outlook; activist Jana escalates for CEO change

  • CooperSurgical sale review ends with no deal, guidance cut Cooper ended its nine-month review and kept CooperSurgical because bids were too low, then reported a weak quarter and cut its outlook. Shares fell about 15% to a 52-week low near $51, as investors lost hope a sale would unlock value.

    This is the period's biggest negative force on COO's price and the core reason it is moving.

  • New $1 billion buyback authorized alongside the no-sale decision The board approved a fresh $1 billion share repurchase to show confidence in keeping CooperSurgical. Buying back stock shrinks the number of shares and can support the price, but it did not offset the drop from the weak outlook.

    It is the main offsetting positive action announced with the negative review outcome.

  • New innovation hub and six lens product advances CooperVision opened a global innovation hub in England and unveiled six contact-lens advances, including myopia-control and silicone hydrogel products launching over several years. The stock rose 1.4% on the news, a modest lift to the long-term growth story.

    It is a genuinely new positive development supporting future revenue growth.

  • Jana escalates, pushing to replace CEO and sell businesses Jana Partners is pressing Cooper to replace CEO Albert White and the board chair and to explore selling CooperVision or CooperSurgical, threatening a proxy fight. The stock is down about 28% since Jana first disclosed its stake, keeping pressure on management.

    It is the latest activist escalation and a key force behind the stock's uncertainty.

September 2026
▲2▼1

Cooper cuts guidance, keeps CooperSurgical; activist Jana pushes for sale

  • Guidance cut and strategic review ends with CooperSurgical retained Cooper cut its fiscal 2026 revenue and profit outlook below what analysts expected and decided to keep its women's health unit, CooperSurgical, instead of selling it. The weak forecast and no-sale decision sent the stock down sharply, because investors had hoped a sale would unlock value.

    This is the main new event that drove the stock down this period.

  • Buyback expanded to $3 billion Alongside the weak guidance, Cooper increased its share buyback program from $2 billion to $3 billion, leaving about $1.5 billion available. Buying back more stock can support the share price by reducing the number of shares outstanding, but it did not offset the negative reaction to the guidance cut.

    This is a new capital action that partially offsets the negative guidance news.

  • Activist Jana Partners pushes for sale and CEO change Activist investor Jana Partners sent a letter urging Cooper to pursue a sale, replace its CEO, and consider selling assets. The stock rose 1.7% after hours on the news, as investors saw a chance for a shake-up that could boost value after a 34% year-to-date decline.

    This is the latest new development that could change the company's direction and stock price.

▲2▼1

Cooper cuts guidance, keeps CooperSurgical; activist Jana pushes for sale

  • Guidance cut and strategic review ends with CooperSurgical retained Cooper cut its fiscal 2026 revenue and profit outlook below what analysts expected and decided to keep its women's health unit, CooperSurgical, instead of selling it. The weak forecast and no-sale decision sent the stock down sharply, because investors had hoped a sale would unlock value.

    This is the main new event that drove the stock down this period.

  • Buyback expanded to $3 billion Alongside the weak guidance, Cooper increased its share buyback program from $2 billion to $3 billion, leaving about $1.5 billion available. Buying back more stock can support the share price by reducing the number of shares outstanding, but it did not offset the negative reaction to the guidance cut.

    This is a new capital action that partially offsets the negative guidance news.

  • Activist Jana Partners pushes for sale and CEO change Activist investor Jana Partners sent a letter urging Cooper to pursue a sale, replace its CEO, and consider selling assets. The stock rose 1.7% after hours on the news, as investors saw a chance for a shake-up that could boost value after a 34% year-to-date decline.

    This is the latest new development that could change the company's direction and stock price.

Neogen Corporation (NEOG)

Q3 2026
▲3▼1

Neogen's growth bets meet an FDA safety blow

  • Q4 beat and strong FY27 guidance Neogen's fiscal fourth-quarter revenue of $225.3 million beat expectations, with core growth accelerating to 4.3% and adjusted EBITDA up 12%. It guided fiscal 2027 revenue to $880–885 million and EBITDA to $180–182 million, and repaid $20 million of debt. A stronger profit outlook lifts the stock.

    The earnings beat and guidance are the core reason the stock jumped and set the period's direction.

  • R&D boost and Petrifilm brought in-house Neogen plans to raise fiscal 2027 R&D spending about 50% and move Petrifilm manufacturing in-house, with the first sellable output starting November 2026 and at least two new product launches a year. Doing its own manufacturing can cut costs and speed new products, supporting future profit.

    This is a concrete new investment plan that shapes Neogen's growth and margins beyond the quarter.

  • FDA warning letters over contaminated horse product The FDA issued warning letters after fungal contamination was found in Neogen's veterinary product HYCOAT, linked to severe joint infections in nearly 100 horses and at least 20 deaths. Shares fell 5.4%. This raises regulatory, legal and reputational risk that can weigh on the stock.

    It is the main negative force this period and a real counterweight to the upbeat earnings news.

  • Guidance raised again above consensus Neogen lifted fiscal year revenue guidance to $885–890 million, above its earlier range and the $883.2 million consensus, sending shares up 11% before the market opened. The raise signals management sees demand holding up, which supports the stock.

    The fresh guidance increase is the newest positive catalyst and confirms the growth trend.

August 2026
▲3▼1

Neogen's growth bets meet an FDA safety blow

  • Q4 beat and strong FY27 guidance Neogen's fiscal fourth-quarter revenue of $225.3 million beat expectations, with core growth accelerating to 4.3% and adjusted EBITDA up 12%. It guided fiscal 2027 revenue to $880–885 million and EBITDA to $180–182 million, and repaid $20 million of debt. A stronger profit outlook lifts the stock.

    The earnings beat and guidance are the core reason the stock jumped and set the period's direction.

  • R&D boost and Petrifilm brought in-house Neogen plans to raise fiscal 2027 R&D spending about 50% and move Petrifilm manufacturing in-house, with the first sellable output starting November 2026 and at least two new product launches a year. Doing its own manufacturing can cut costs and speed new products, supporting future profit.

    This is a concrete new investment plan that shapes Neogen's growth and margins beyond the quarter.

  • FDA warning letters over contaminated horse product The FDA issued warning letters after fungal contamination was found in Neogen's veterinary product HYCOAT, linked to severe joint infections in nearly 100 horses and at least 20 deaths. Shares fell 5.4%. This raises regulatory, legal and reputational risk that can weigh on the stock.

    It is the main negative force this period and a real counterweight to the upbeat earnings news.

  • Guidance raised again above consensus Neogen lifted fiscal year revenue guidance to $885–890 million, above its earlier range and the $883.2 million consensus, sending shares up 11% before the market opened. The raise signals management sees demand holding up, which supports the stock.

    The fresh guidance increase is the newest positive catalyst and confirms the growth trend.

Latest
▲3▼1

Neogen's growth bets meet an FDA safety blow

  • Q4 beat and strong FY27 guidance Neogen's fiscal fourth-quarter revenue of $225.3 million beat expectations, with core growth accelerating to 4.3% and adjusted EBITDA up 12%. It guided fiscal 2027 revenue to $880–885 million and EBITDA to $180–182 million, and repaid $20 million of debt. A stronger profit outlook lifts the stock.

    The earnings beat and guidance are the core reason the stock jumped and set the period's direction.

  • R&D boost and Petrifilm brought in-house Neogen plans to raise fiscal 2027 R&D spending about 50% and move Petrifilm manufacturing in-house, with the first sellable output starting November 2026 and at least two new product launches a year. Doing its own manufacturing can cut costs and speed new products, supporting future profit.

    This is a concrete new investment plan that shapes Neogen's growth and margins beyond the quarter.

  • FDA warning letters over contaminated horse product The FDA issued warning letters after fungal contamination was found in Neogen's veterinary product HYCOAT, linked to severe joint infections in nearly 100 horses and at least 20 deaths. Shares fell 5.4%. This raises regulatory, legal and reputational risk that can weigh on the stock.

    It is the main negative force this period and a real counterweight to the upbeat earnings news.

  • Guidance raised again above consensus Neogen lifted fiscal year revenue guidance to $885–890 million, above its earlier range and the $883.2 million consensus, sending shares up 11% before the market opened. The raise signals management sees demand holding up, which supports the stock.

    The fresh guidance increase is the newest positive catalyst and confirms the growth trend.